Britain will pursue a hard Brexit and leave the EU single market sending the stock market down to a lower open with the Dow slipping 22 points to 19,863. Nasdaq fell 22 points to 5,551.
On the upside
The European Commission granted Orphan Drug Designation to Benitec Biopharma's (Nasdaq: BNTC) oculopharyngeal muscular dystrophy treatment BB-301.
Clayton Williams Energy (NYSE: CWEI) will be acquired by Noble Energy (NYSE: NBL) for a premium of approximately $2.7 billion in cash and stock including the assumption of debt.
The Environmental Protection Agency approved the pathway for isobutnol that is produced by Gevo (Nasdaq: GEVO) to be an advanced biofuel under the Renewable Fuel Standard Program.
On the downside
Alcobra (Nasdaq: ADHD) reported disappointing results from a Phase 3 clinical trial of Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder in adult patients.
The Customs and Border Patrol agency will reinstate a ban on Arista Networks' (NYSE: ANET) network switches.
Christopher & Banks (NYSE: CBK) cut its fourth quarter revenue forecast, widened expected fourth quarter losses and announced the departure of chief executive LuAnn Via.
In the broad market, advancing issues outpaced decliners by a margin of more than 10 to 9 on the NYSE while decliners edged out advancers by more than 2 to 1 on Nasdaq. The broader S&P 500 index lost 4 points to 2,269. Bitcoin leaped $53 to $876.
